Jeff Yass’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-407,400
| Closed | -$3.68M | – | 14205 |
|
|
2025
Q4 | $3.68M | Buy |
407,400
+380,700
| +1,426% | +$2.85M | ﹤0.01% | 4533 |
|
|
2025
Q3 | $83K | Sell |
26,700
-5,600
| -17% | -$14.8K | ﹤0.01% | 11665 |
|
|
2025
Q2 | $69.1K | Buy |
32,300
+13,100
| +68% | +$21.2K | ﹤0.01% | 11994 |
|
|
2025
Q1 | $22.1K | Sell |
19,200
-69,700
| -78% | -$120K | ﹤0.01% | 12088 |
|
|
2024
Q4 | $195K | Buy |
88,900
+43,800
| +97% | +$99.3K | ﹤0.01% | 10753 |
|
|
2024
Q3 | $98.3K | Sell |
45,100
-157,400
| -78% | -$362K | ﹤0.01% | 11061 |
|
|
2024
Q2 | $468K | Buy |
202,500
+69,900
| +53% | +$290K | ﹤0.01% | 8429 |
|
|
2024
Q1 | $729K | Buy |
132,600
+101,000
| +320% | +$462K | ﹤0.01% | 7614 |
|
|
2023
Q4 | $78.1K | Sell |
31,600
-59,900
| -65% | -$569K | ﹤0.01% | 11494 |
|
|
2023
Q3 | $3.18M | Sell |
91,500
-70,500
| -44% | -$2.44M | ﹤0.01% | 4274 |
|
|
2023
Q2 | $5.31M | Buy |
162,000
+127,000
| +363% | +$4.38M | ﹤0.01% | 3423 |
|
|
2023
Q1 | $1.17M | Buy |
+35,000
| New | +$1.36M | ﹤0.01% | 6399 |
|
|
2022
Q4 | – | Sell |
-35,800
| Closed | -$1.25M | – | 13801 |
|
|
2022
Q3 | $1.25M | Buy |
+35,800
| New | +$793K | ﹤0.01% | 6056 |
|
Other funds holding VTYX
Jeff Yass's VTYX Position: Q1 2026 in Review
Jeff Yass sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,118,275 shares — an estimated $10.1M sold.
Jeff Yass first reported a position in VTYX in Q3 2022 and held it in 12 quarters. The position peaked at $10.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Jeff Yass reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 1,118,275 Ventyx Biosciences shares in Q1 2026, an estimated $10.1M.
- Jeff Yass first reported a position in Ventyx Biosciences in Q3 2022 and held it in 12 quarters.
- Jeff Yass's Ventyx Biosciences position peaked at $10.1M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.